Featured Research

from universities, journals, and other organizations

Progress Toward An Alzheimer’s Drug That Saves Brain Cells

Date:
March 20, 2009
Source:
VIB (the Flanders Institute for Biotechnology)
Summary:
Scientists have identified a molecule that can form the basis for a new therapy for Alzheimer's disease. This is the first step toward a medicine that could actually stop the progress of Alzheimer's. Existing medicines can at best limit the loss of memory during the first phases of the disease.

VIB scientists connected to the K.U.Leuven have identified a molecule that can form the basis for a new therapy for Alzheimer’s disease.  This is the first step toward a medicine that could actually stop the progress of Alzheimer’s. Existing medicines can at best limit the loss of memory during the first phases of the disease.

Related Articles


The journal Science is publishing the results of this research. A first step, however, is still a long way from an approved drug − even if everything goes well, it will be another 15 years before the medicine becomes available.

Alzheimer’s disease

Alzheimer’s disease is the most prevalent form of dementia in the Western world. The disease’s harmful effects on memory and mental functioning make it one of the most terrifying syndromes. It is estimated that, by 2010, our country will have more than 150,000 Alzheimer’s patients. At present, this disease is still incurable. Today’s medicines for Alzheimer’s patients sustain the memory functions for a short time, but they do not stop the brain’s cells from dying off.

Plaques and the γ-secretase complex

A typical characteristic of the brains of Alzheimer’s patients is the presence of amyloid plaques, which are abnormal accumulations of the β-amyloid protein between the neurons. The sticky β-amyloid arises when the amyloid precursor protein is cut into pieces incorrectly.

The γ-secretase complex − which cuts proteins at a specific place − plays a major role in the creation of these plaques. However, this complex (group of proteins that work together) is also involved in the regulation of a series of other essential proteins such as Notch, which plays a crucial role in the development of an embryo. This is why many of the medicines in development that act on the whole γ-secretase complex run up against toxic side effects.

Aph1B

Under the direction of Bart De Strooper, and in collaboration with researchers in other countries, Lutgarde Serneels, Jιrτme Van Biervliet and their colleagues have been studying the γ-secretase complex in a variety of tissues. They have now been able to demonstrate that the complex assumes a different shape and function according to the tissue in which the secretase is active. For their research on Alzheimer’s disease, the researchers have used mouse models. They have found that deactivating the variant, Aph1B γ-secretase, in Alzheimer mice leads to reduced formation of the plaques, without any harmful side effects.

Importance of the research

With this discovery, the researchers are once again opening a way toward the development of medicines that deactivate γ-secretase. By concentrating on a variant of the complex that cuts proteins specifically in the brain − the Aph1B γ-secretase complex − the formation of the plaques can be prevented, while the other functions of γ-secretase are not affected. This raises hopes for a drug that, for the first time, will succeed in stopping Alzheimer’s disease. Furthermore, because the toxic side effects have been cut away, it could also be administered preventively to persons with a risk of Alzheimer’s. However, such a medicine will still require at least a good 15 years of further research and development.

Given the fact that γ-secretase is also involved in the onset of certain cancers, research on the various variants of γ-secretase can lead to new insights into these diseases as well.


Story Source:

The above story is based on materials provided by VIB (the Flanders Institute for Biotechnology). Note: Materials may be edited for content and length.


Journal Reference:

  1. Serneels et al. γ-secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer’s Disease. Science, March 20, 2009

Cite This Page:

VIB (the Flanders Institute for Biotechnology). "Progress Toward An Alzheimer’s Drug That Saves Brain Cells." ScienceDaily. ScienceDaily, 20 March 2009. <www.sciencedaily.com/releases/2009/03/090319104027.htm>.
VIB (the Flanders Institute for Biotechnology). (2009, March 20). Progress Toward An Alzheimer’s Drug That Saves Brain Cells. ScienceDaily. Retrieved January 26, 2015 from www.sciencedaily.com/releases/2009/03/090319104027.htm
VIB (the Flanders Institute for Biotechnology). "Progress Toward An Alzheimer’s Drug That Saves Brain Cells." ScienceDaily. www.sciencedaily.com/releases/2009/03/090319104027.htm (accessed January 26, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Monday, January 26, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Technology Is Ruining Snow Days For Students

How Technology Is Ruining Snow Days For Students

Newsy (Jan. 25, 2015) — More schools are using online classes to keep from losing time to snow days, but it only works if students have Internet access at home. Video provided by Newsy
Powered by NewsLook.com
Weird Things Couples Do When They Lose Their Phone

Weird Things Couples Do When They Lose Their Phone

BuzzFeed (Jan. 24, 2015) — Did you back it up? Do you even know how to do that? Video provided by BuzzFeed
Powered by NewsLook.com
Smart Wristband to Shock Away Bad Habits

Smart Wristband to Shock Away Bad Habits

Reuters - Innovations Video Online (Jan. 23, 2015) — A Boston start-up is developing a wristband they say will help users break bad habits by jolting them with an electric shock. Ben Gruber reports. Video provided by Reuters
Powered by NewsLook.com
Amazing Technology Allows Blind Mother to See Her Newborn Son

Amazing Technology Allows Blind Mother to See Her Newborn Son

RightThisMinute (Jan. 23, 2015) — Not only is Kathy seeing her newborn son for the first time, but this is actually the first time she has ever seen a baby. Kathy and her sister, Yvonne, have been legally blind since childhood, but thanks to an amazing new technology, eSight glasses, which gives those who are legally blind the ability to see, she got the chance to see the birth of her son. It&apos;s an incredible moment and an even better story. Video provided by RightThisMinute
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins